Who benefits, more, from LL being successful?
US Govt & insurance providers for starters.

Their costs dwarfs, pharmas preferences.

Instead of constant projecting 1,2,3 pharmas having a ghost lock on LL, realize once we raise the $$, & hopefully interim is phenomenal...........it's a wrap for any pharma company. Any.

This becomes far beyond the reach of 3 companies or so. They will not control world-wide markets, doctors, marketing, articles &/or, news coverage & especially social media excitement.

Initial results allow considering totally new business models, that pharma will be excluded from, if they are not careful.

Pharma is absolutely close to finding itsself in an unprecedented position of needing to pic battles, of a future war, they simply will not win.

FDA is & will, greenlight Leronlimab as it progresses.

1last thing --- top of my head, aren't many current "soc" drugs, pretty far along in their patent cycles

Only few weeks from funding or not.
So many things moving in tandem.

Shall see....